324 related articles for article (PubMed ID: 30689020)
1. Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction.
Rørth R; Dewan P; Kristensen SL; Jhund PS; Petrie MC; Køber L; McMurray JJV
Clin Res Cardiol; 2019 Aug; 108(8):868-877. PubMed ID: 30689020
[TBL] [Abstract][Full Text] [Related]
2. Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
Fishbein DP; Hellkamp AS; Mark DB; Walsh MN; Poole JE; Anderson J; Johnson G; Lee KL; Bardy GH;
J Am Coll Cardiol; 2014 Jun; 63(23):2560-2568. PubMed ID: 24727258
[TBL] [Abstract][Full Text] [Related]
3. Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes.
Sharma A; Al-Khatib SM; Ezekowitz JA; Cooper LB; Fordyce CB; Michael Felker G; Bardy GH; Poole JE; Thomas Bigger J; Buxton AE; Moss AJ; Friedman DJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Peterson ED; Inoue LYT; Sanders GD
Eur J Heart Fail; 2018 Jun; 20(6):1031-1038. PubMed ID: 29761861
[TBL] [Abstract][Full Text] [Related]
4. New York Heart Association functional class and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: Extended follow-up of the DANISH trial.
Karacan MN; Doi SN; Yafasova A; Thune JJ; Nielsen JC; Haarbo J; Bruun NE; Gustafsson F; Eiskjær H; Hassager C; Svendsen JH; Høfsten DE; Pehrson S; Køber L; Butt JH
Eur J Heart Fail; 2024 Jun; 26(6):1423-1431. PubMed ID: 38733253
[TBL] [Abstract][Full Text] [Related]
5. Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial.
Adabag S; Patton KK; Buxton AE; Rector TS; Ensrud KE; Vakil K; Levy WC; Poole JE
JAMA Cardiol; 2017 Jul; 2(7):767-774. PubMed ID: 28724134
[TBL] [Abstract][Full Text] [Related]
6. The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure.
Rørth R; Thune JJ; Nielsen JC; Haarbo J; Videbæk L; Korup E; Signorovitch J; Bruun NE; Eiskjær H; Hassager C; Svendsen JH; Høfsten DE; Torp-Pedersen C; Pehrson S; Køber L; Kristensen SL
Europace; 2019 Aug; 21(8):1203-1210. PubMed ID: 31323662
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT.
Poole JE; Olshansky B; Mark DB; Anderson J; Johnson G; Hellkamp AS; Davidson-Ray L; Fishbein DP; Boineau RE; Anstrom KJ; Reinhall PG; Packer DL; Lee KL; Bardy GH;
J Am Coll Cardiol; 2020 Jul; 76(4):405-415. PubMed ID: 32703511
[TBL] [Abstract][Full Text] [Related]
8. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
Packer DL; Prutkin JM; Hellkamp AS; Mitchell LB; Bernstein RC; Wood F; Boehmer JP; Carlson MD; Frantz RP; McNulty SE; Rogers JG; Anderson J; Johnson GW; Walsh MN; Poole JE; Mark DB; Lee KL; Bardy GH
Circulation; 2009 Dec; 120(22):2170-6. PubMed ID: 19917887
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy.
Briongos-Figuero S; Estévez A; Pérez ML; Martínez-Ferrer JB; García E; Viñolas X; Arenal Á; Alzueta J; Muñoz-Aguilera R
ESC Heart Fail; 2020 Feb; 7(1):279-283. PubMed ID: 31823514
[TBL] [Abstract][Full Text] [Related]
10. Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure.
Fudim M; Ali-Ahmed F; Parzynski CS; Ambrosy AP; Friedman DJ; Pokorney SD; Curtis JP; Fonarow GC; Masoudi FA; Hernandez AF; Al-Khatib SM
JAMA Cardiol; 2020 Jun; 5(6):643-651. PubMed ID: 32211811
[TBL] [Abstract][Full Text] [Related]
11. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus.
Sharma A; Wu J; Xu H; Hernandez A; Felker GM; Al-Khatib S; Green J; Matsouaka R; Fonarow GC; Singh JP; Heidenreich PA; Ezekowitz JA; DeVore A
J Am Heart Assoc; 2020 Jun; 9(12):e012405. PubMed ID: 32476539
[TBL] [Abstract][Full Text] [Related]
13. Patient barriers to implantable cardioverter defibrillator implantation for the primary prevention of sudden cardiac death in patients with heart failure and reduced ejection fraction.
Chan LL; Lim CP; Aung ST; Quetua P; Ho KL; Chong D; Teo WS; Sim D; Ching CK
Singapore Med J; 2016 Apr; 57(4):182-7. PubMed ID: 27075476
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients.
Jukema JW; Timal RJ; Rotmans JI; Hensen LCR; Buiten MS; de Bie MK; Putter H; Zwinderman AH; van Erven L; Krol-van Straaten MJ; Hommes N; Gabreëls B; van Dorp W; van Dam B; Herzog CA; Schalij MJ; Rabelink TJ;
Circulation; 2019 Jun; 139(23):2628-2638. PubMed ID: 30882234
[TBL] [Abstract][Full Text] [Related]
15. Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF.
Segar MW; Keshvani N; Singh S; Patel L; Parsa S; Betts T; Reeves GR; Mentz RJ; Forman DE; Razavi M; Saeed M; Kitzman DW; Pandey A
JACC Heart Fail; 2024 Apr; 12(4):757-767. PubMed ID: 37565972
[TBL] [Abstract][Full Text] [Related]
16. A comparison of anti-arrhythmic efficacy of carvedilol vs metoprolol succinate in patients with implantable cardioverter-defibrillators.
Ayan M; Habash F; Alqam B; Gheith Z; Cross M; Vallurupalli S; Paydak H
Clin Cardiol; 2019 Feb; 42(2):299-304. PubMed ID: 30592068
[TBL] [Abstract][Full Text] [Related]
17. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Bardy GH; Lee KL; Mark DB; Poole JE; Packer DL; Boineau R; Domanski M; Troutman C; Anderson J; Johnson G; McNulty SE; Clapp-Channing N; Davidson-Ray LD; Fraulo ES; Fishbein DP; Luceri RM; Ip JH;
N Engl J Med; 2005 Jan; 352(3):225-37. PubMed ID: 15659722
[TBL] [Abstract][Full Text] [Related]
18. Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
Chen J; Johnson G; Hellkamp AS; Anderson J; Mark DB; Lee KL; Bardy GH; Poole JE
J Am Coll Cardiol; 2013 May; 61(21):2161-8. PubMed ID: 23541974
[TBL] [Abstract][Full Text] [Related]
19. SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death.
Au-Yeung WT; Reinhall PG; Poole JE; Anderson J; Johnson G; Fletcher RD; Moore HJ; Mark DB; Lee KL; Bardy GH
Heart Rhythm; 2015 Oct; 12(10):2058-66. PubMed ID: 26096609
[TBL] [Abstract][Full Text] [Related]
20. Predictors of primary prevention implantable cardioverter-defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all-cause mortality.
Schrage B; Lund LH; Benson L; Dahlström U; Shadman R; Linde C; Braunschweig F; Levy WC; Savarese G
Eur J Heart Fail; 2022 Jul; 24(7):1212-1222. PubMed ID: 35502681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
